PureTech Health LLC

ALIVIO

drug delivery system comprising pharmacological compositions and formulations for the delivery of therapeutic, prophylactic, or diagnostic agents; house mark for therapeutic products and devices;research and development in the pharmaceutical, biotechnology, and digital medicine fields;

ALIVIO THERAPEUTICS

drug delivery system comprising pharmacological compositions and formulations for the delivery of therapeutic, prophylactic, or diagnostic agents; house mark for therapeutic products and devices;research and development in the pharmaceutical, biotechnology, and digital medicine fields;

ARIYA

Immunotherapeutic agents, namely, antibodies, vaccines, and pharmaceutical preparations thereof for the treatment of cancer and neurodegenerative, neurodevelopmental and cognitive disorders; Therapeutic agents for transport and delivery of small molecules and biologics to the lymphatic system; Exosome-based pharmaceutical preparations to facilitate the oral administration and delivery of therapeutic agents; pharmaceutical preparations for the modulation of lymphatic function in the brain for the treatment, prevention, and delayed onset of central nervous system disorders, Alzheimer's disease, Huntington's disease, age-associated cognitive decline and diseases associated with neurodegenerative, neurodevelopmental and cognitive disorders; Therapeutic agents for the treatment of fibrotic diseases, namely, interstitial lung disease, pulmonary fibrosis, lymphedema, sclerosis, and scleroderma;

BIG

House mark for pharmaceutical compositions as prophylaxis, diagnostics or treatments for human and animal disease and illness, namely infectious diseases, inflammatory disorders, respiratory diseases, cardiovascular diseases, autoimmune disorders, gastrointestinal disorders, cancer, hematological diseases, neurological diseases, hepatic diseases, renal diseases, lymphatic disorders, metabolic disorders, genetic disorders, dermatological disorders, ocular diseases, and orphan disease and drug delivery agents and formulations consisting of compounds that facilitate the delivery of a wide range of pharmaceuticals and other chemical, synthetic or biologic payloads that can be administered in a range of approaches;research and development in the pharmaceutical, biotechnology, and digital medicine fields;

BIG

The mark consists of the letters B I G with a fanciful curvilinear design above the lettering and, inversely, below the lettering.;House mark for pharmaceutical compositions as prophylaxis, diagnostics or treatments for human and animal disease and illness, namely infectious diseases, inflammatory disorders, respiratory diseases, cardiovascular diseases, autoimmune disorders, gastrointestinal disorders, cancer, hematological diseases, neurological diseases, hepatic diseases, renal diseases, lymphatic disorders, metabolic disorders, genetic disorders, dermatological disorders, ocular diseases, and orphan disease and drug delivery agents and formulations consisting of compounds that facilitate the delivery of a wide range of pharmaceuticals and other chemical, synthetic or biologic payloads that can be administered in a range of approaches;research and development in the pharmaceutical, biotechnology, and digital medicine fields;